AC8 has all the necessary licenses to grow and manufacture cannabinoid medicines in Australia.
Showing 25 of 243
New research corroborates the company’s direction of studying the use of NRGBiotic™ to improve gut health.
CPAT-01 is CP1’s lead pharmaceutical product and is derived from cannabinoids.
The ICCI provides access to a global network of specialist services.
AusCann is a fully integrated early-mover pharmaceutical cannabinoid company.
The Vancouver-based medicinal cannabis grower’s Queensland facility will be the world's largest greenhouse cannabis operation, covering a 99-acre site
The property is set to be used for production of medicinal cannabis
The company aims to be vertically integrated from farm through to end-products.
Zelda has released its December quarterly report confirming multiple trials are on track.
Along with Priceline, more than 2100 independent pharmacies will also be able to access Medlab’s nutraceutical range.
The company has reaffirmed its upcoming milestones as it confirmed December quarter achievements.
The facility will support the development of existing and new cannabinoid formulations.
A phase I study in Australia is evaluating a cannabis spray therapeutic in cancer patients.
DayaCann is a 50:50 joint venture formed by AusCann and Chilean partner Fundación Daya.
Drug registration of NanaBis in Europe is a key part of Medlab’s plans and the SME qualification allows it to start the process.
The incoming CFO is a Canadian national with relevant in-country experience.
Non-executive director Rob Clifford now holds more than 480,000 shares in an indirect interest.
NanoStat™ refers to the delivery of the drug Atorvastatin using NanoCelle™.
This is an important milestone towards full-scale medicinal cannabis production in Australia.
Executive director Dr Paul MacLeman will act as interim CEO from January 1, 2019 until a full-time appointment is made by the board.
CannPal’s aim is to be one of the first companies to provide veterinarians with GMP-produced and regulatory approved cannabinoid-derived therapeutics for pets.
A deal has been done with SUDA, a global leader in oro-mucosal drug delivery.
Yesterday, Medlab revealed it had made progress expanding cannabis-based medicines into Europe.
By having a European subsidiary, Medlab can save on drug registration fees.
THC Global has expanded into New Zealand's medicinal cannabis market.